Park City, UT

3 days / 6 sessions
Current Issues in Spine

February 2-4, 2017

AEROBIOTIX-Logo-STACKED-small-1-1.png

July 9, 2018 OrthoSpineNews

May 25, 2018

LOMA LINDA, Calif.–(BUSINESS WIRE)–In the fight against hospital acquired infections, Veterans Administration medical centers play a critical role in protecting the health of America’s veterans. At the 159-bed Veterans Administration Loma Linda Healthcare System in California, administrators have adopted the latest technology in fighting airborne bacteria and viruses which contribute to these infections. Recently, the hospital adopted the Illuvia system by Aerobiotix, a unique technology which utilizes ultraviolet energy to eliminate airborne pathogens in the hospital environment. This includes drug resistant microbes such as MRSA. “The hardest place to kill a pathogen is inside the human body. If we can eliminate the danger in the air before it gets a chance to enter the patient, the human and economic benefits are profound,” states Dr. David Kirschman, M.D. founder of Aerobiotix, Inc.

The Veterans Administration Loma Linda has installed the Illuvia systems in ten hospital locations including operating rooms and surgical supply areas. In peer reviewed data, these systems have been shown to significantly reduce airborne bacterial and contamination levels.

About Aerobiotix Inc.

Aerobiotix, Inc. is a company driving leadership in advanced air quality products for the healthcare market. The company develops, manufactures and markets novel technologies to build better healthcare environments worldwide. Our focus is to build awareness of the contribution of air quality issues to hospital-acquired infections and provide safe, effective devices to improve the environments of care. Today, our products benefit patients and caregivers around the globe.

Contacts

Aerobiotix, Inc.
Ann Dunham
Department of Marketing
adunham@aerobiotix.com


Calcium-Phosphate-Bone-Cement-390x220-12-1.png

July 9, 2018 OrthoSpineNews

(EMAILWIRE.COM, July 09, 2018 ) Bone Cement Market

Bone cement is used for the fixation of prosthesis to the bone in various orthopedic musculoskeletal surgical procedures for the treatment of osteoporosis, osteoarthritis, rheumatoid arthritis, traumatic arthritis, avascular necrosis, severe joint destruction secondary to trauma, collagen disease, and revision of previous arthroplasty.

In our study, we have segmented the bone cement market by type, application, and end user. Based on type, global bone cement market is segmented as polymethyl methacrylate (PMMA) cement, calcium phosphate cement (CPC), glass polyalkenoate cement (GPC), and others. Based on application, the market is segmented into arthroplasty, kyphoplasty, and vertebroplasty. On the basis of end user, the market is segmented as hospitals, ambulatory surgery centers, and clinics. Geographically, the market for bone cement is segmented into North America, Europe, Asia Pacific (APAC), Middle East and Africa (MEA) and South and Central America (S&CAM).

Download Sample Copy @ http://bit.ly/2yVvDWm

The bone cement market is estimated to grow at a CAGR of 5.4% during the forecast period from 2018 to 2025. The market for bone cement is projected to reach US$ 1,414.1 Mn in 2025. The market is witnessing a potential growth rate during the past few years and is expected to witness similar trend in the coming years. Factors such as, increasing prevalence of osteoporosis, growing demand for arthroplasty procedures, and growing geriatric population are primarily contributing to the growth of this market. Additionally, major manufacturers in the market are engaged in research and development activities to develop advanced products. Furthermore, rise in umber of osteoporosis cases and increase in number of bone disease cases are expected to boost the demand for bone cement in the coming years. According to a survey conducted by International Osteoporosis Foundation, around 15-30% male and 30-50% females are at a risk of suffering from osteoporotic fracture during their lifetime. Moreover, according to the International Osteoporosis Foundation, approximately one out of five men and one in every three women over the age of 50 would suffer from a fracture owing to osteoporosis. This is expected to stimulate the demand of bone cement market in the coming years. However, availability of substitutes can hamper the growth of this market at a certain extent.

 

READ THE REST HERE

 


download-123.png

July 9, 2018 OrthoSpineNews

CARLSBAD, Calif., July 09, 2018 (GLOBE NEWSWIRE) — Aurora Spine Corporation (TSXV:ASG) (“Aurora Spine” or the “Company”) announced today the 100th surgical implantation of the company’s ZIP ULTRA® minimally invasive interspinous device in Canada. These surgeries are part of Aurora Spine’s continuing efforts to expand the use of the Company’s ZIP® MIS Fusion System in North America.

The 100th surgery was completed with a ZIP implant provided by Venture Medical, Ltd. and performed at False Creek Healthcare Centre in Vancouver, BC by Navraj Heran, MD, the center’s Chief of Neurosurgery.

“The Aurora Spine ZIP ULTRA MIS fusion system is a very intuitive and easy to use system that allows me to perform a short and safe surgery while avoiding the risk of nerve impact,” said Dr. Heran. “The ZIP device is minimally invasive and the implantation is fast and simple via a small incision.”

“We are very excited to continue offering our ZIP MIS products in Canada,” said Laszlo Garamszegi, Chief Technology Officer and VP of Engineering of Aurora Spine. “The ZIP family of products is designed to be simple, safe and secure with minimal disruption to patients and we are convinced that ZIP implants will contribute to improved patient outcomes in Canada.”

Aurora Spine’s patented ZIP ULTRA MIS interspinous fixation implant for spinal fusion consists of the ONE-STEP™ locking mechanism, which eliminates the use of a set screw, articulating spikes and various sizes to accommodate variations in patient anatomy.

“We are passionate about delivering innovative, first-class products like the ZIP spinal implant to the Canadian market,” said Chris Walsh, President and CEO of Venture Medical, Ltd. “The ZIP implant device is proven to be one of the most significant, minimally invasive technology solutions in the Canadian healthcare market.”

About Dr. Heran

Dr. Navraj Heran is a locally raised and practicing neurosurgeon maintaining a very active neurosurgical profile at several hospitals in the Greater Vancouver area including Royal Columbian Hospital, Eagle Ridge Hospital and Lion’s Gate Hospital. He is specialized in minimal access techniques in neurospine, neurosurgery and endovascular neurosurgery.

About False Creek Healthcare Centre

False Creek Healthcare Centre in Vancouver, BC was founded in 1996 and has grown to become one of Canada’s most renowned independent health providers. This state-of-the-art centre is more than just a medical clinic; it offers world-class service to individuals seeking immediate access to high quality medical care in Canada, utilizing the most advanced technology and techniques available.  Learn more about False Creek Healthcare Centre at their website: https://www.centrichealthsurgical.com/location/vancouver

About the ZIP Implant

“The combination of the proven ONE-STEP™ locking mechanism and our minimally invasive design allows patients in Canada to receive a screwless fusion treatment as a pedicle screw alternative,” said Trent Northcutt, President and CEO of Aurora Spine.

About Aurora Spine

Aurora Spine is an early stage company focused on bringing new solutions to the spinal implant market through a series of screwless, innovative, minimally invasive, regenerative spinal implant technologies. Aurora Spine continues to position itself at the forefront of spinal surgery procedures, focusing on minimally invasive spine surgery technologies. Aurora Spine is changing spine surgery by focusing on disruptive technologies following the Company’s commitment to – Simplifying the Complex.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Information” in Aurora Spine’s final prospectus (collectively, “forward-looking information”). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine’s securities about important factors that could cause Aurora Spine’s actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

CONTACT INFORMATION

Aurora Spine Corporation

Trent Northcutt
President and Chief Executive Officer
(760) 424-2004

Sarina Mason
Chief Financial Officer
(760) 424-2004

www.aurora-spine.com


misonix_01-2-bto2.jpg

July 9, 2018 OrthoSpineNews

FARMINGDALE, N.Y., July 09, 2018 (GLOBE NEWSWIRE) — Misonix, Inc. (NASDAQ:MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced today the results of a new Randomized Controlled Trial (RCT), which demonstrated superior healing outcomes associated with the use of ultrasonic debridement for lower extremity wounds.

The study, “The effect of 22.5kHz low frequency contact ultrasound debridement (LFCUD) on lower extremity wound healing for a vascular surgery population: A Randomized Controlled Trial” – was published in the International Wound Journal, and compared Misonix’s SonicOne® ultrasonic debridement device to standard sharp debridement in a 70 patient study conducted by The Ottawa Hospital: Limb Preservation Program in Ottawa, Canada. It concluded that SonicOne ultrasonic debridement treatment resulted in better wound appearance, significant reduction in wound area and superior healing outcomes, compared to other patients in the study that were not treated with SonicOne.

Stavros Vizirgianakis, President and CEO of Misonix, commented, “We are very proud to partner with world class wound care facilities like The Ottawa Hospital: Limb Preservation Program. These results from their recently published study are important both because of the study’s rigor and its conclusive data, which shows marked improvement in healing rates and effectiveness of our SonicOne ultrasonic technology to positively and significantly impact patients’ lives. Wound treatment is an attractive growth opportunity for Misonix and we are confident that our best-in-class ultrasound wound treatment products will allow us to significantly grow across both existing and new markets and drive added adoption of our therapeutic ultrasonic medical devices, including SonicOne.”

Dr. Christine Murphy, lead author of the study, said, “This detailed work is strong evidence that SonicOne improves tissue quality in a challenging population facing very high risk of amputation, including more wound closures. A Randomized Controlled Trial is level one evidence and not commonly available for wound technologies, and as an assessor-blinded study, this is very powerful.”

About Misonix, Inc.
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix’s proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s web site at www.misonix.com.

Contact: 
Joe Dwyer Joseph Jaffoni, Norberto Aja, Jennifer Neuman
Chief Financial Officer JCIR
Misonix, Inc. 212-835-8500 or mson@jcir.com
631-694-9555

iga-pill-1-1.png

July 9, 2018 OrthoSpineNews

SAN DIEGOJuly 9, 2018 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced that the first peer-reviewed publication from the NuVasive-sponsored multicenter Integrated Global Alignment (iGA®) study is now available in the journal Spine. This initial study evaluated the preoperative prevalence and incidence of postoperative spinopelvic malalignment in patients who underwent one- or two-level lumbar fusions for degenerative (non-deformity) indications.

Spinopelvic malalignment (i.e., Pelvic Incidence (PI) minus Lumbar Lordosis (LL) greater than or equal to 10°) following lumbar fusion has been shown to be associated with lower postoperative health-related quality of life and elevated risk of adjacent segment failure; however, the incidence of this in short-segment degenerative lumbar fusions from a large sample of patients had been previously unreported.1

The article, “A multicenter radiographic evaluation of the rates of preoperative and postoperative malalignment in degenerative spinal fusions,” reports on the rates of malalignment in nearly 600 patients whose measurements were retrospectively acquired. Researchers measured lateral preoperative and postoperative lumbar radiographs of one- or two-level lumbar fusion patients using the NuVasive iGA platform. The study was conducted at 18 institutions with 24 treating investigators in the United States. Patients were grouped as either aligned (PI-LL<10°) or malaligned (PI-LL≥10°) both pre- and postoperatively.

The results show malalignment is common both before and after short-segment degenerative fusions. Preoperatively, 173 (30 percent) patients undergoing one- or two-level lumbar fusion surgery for degenerative conditions exhibited malalignment and postoperatively, 161 (28 percent) patients were malaligned. These relatively high rates of pre- and postoperative malalignment, even in degenerative cases, demonstrate this is not a deformity-only problem and alignment should be measured in all cases.

“This study further demonstrates that incorporating alignment measurements using iGA into our surgical planning directly translates to our patients and the clinical benefits/outcomes we know are influenced by achieving global spinal alignment,” said Jean-Christophe Leveque, M.D., from the Neuroscience Institute, Virginia Mason Hospital and Medical Center in Seattle. “Alignment in deformity procedures has been relevant for years, but this is the first multicenter study to show just how common malalignment is both before and after short-segment, degenerative fusions. We need to shift our mindset as spine surgeons, recognize these results from simple degenerative cases and start measuring spinopelvic parameters in all of our lumbar fusion cases, especially those that involve L4 through S1.”

The conclusion of the study was that alignment preservation and restoration considerations should be incorporated into the decision-making of all lumbar spinal fusions. Prior to this research, spinal alignment considerations were only thought necessary for spinal deformity cases.

The published results of this study and two additional iGA studies evaluating 1) changes between preoperative standing and intraoperative recumbent alignment and 2) the role of pre- and intraoperative alignment planning on surgical execution and outcomes, will be on the podium at the North American Spine Society (NASS) Annual Meeting in September.

“NuVasive has been focused on the importance of alignment and the impact it has on achieving surgical goals and enhanced clinical outcomes well before we launched iGA in 2015,” said Matt Link, executive vice president, strategy, technology, and corporate development. “We have partnered with some of the largest academic institutions in the country to lead the research efforts and build the scientific evidence to advance the understanding of spinal alignment and the importance it plays in surgical decision-making—further transforming spine and how surgeons approach treatment. These studies are helping drive the future of iGA and adding further value and credibility to our systems-based spine solutions.”

Integrated Global Alignment—Why Alignment Matters™

NuVasive is committed to a global approach for assessing, preserving, and restoring spinal alignment in an effort to promote surgical efficiencies, lasting patient outcomes, and improved quality of life. Integration across the surgical workflow allows the surgeon to confidently and reproducibly calculate, correct and confirm optimal spinal alignment.

To learn more about the NuVasive Integrated Global Alignment platform, visit https://www.nuvasive.com/solutions/iga-integrated-global-alignment/.

About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements

NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

1Leveque JA, Segebarth B, Schroerlucke SR, et al. A multicenter radiographic evaluation of the rates of preoperative and postoperative malalignment in degenerative spinal fusions. Spine 2018;43(13):E782-89.

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com


A430291_1_En_44_Fig3_HTML-bto-2-1.jpg

July 6, 2018 OrthoSpineNews

NORCROSS, Ga., July 5, 2018 /PRNewswire/ — Lipogems, a leader in medical technologies for orthopaedic physicians, announced U.S. Food and Drug Administration (FDA) clearance of the company’s Lipogems Microfragmented Adipose Tissue Transplant System.  Federal regulators have cleared the way for this exciting new device and technology to be used in orthopaedic and arthroscopic procedures. Lipogems successfully uses a patient’s own body fat (known clinically as adipose tissue) to assist in the healing process and, in some cases, used in conjunction with traditional orthopaedic surgery. Lipogems is attractive to orthopaedic physicians because it is compliant with the latest FDA guidelines and is cleared for use in orthopaedics and arthroscopic surgery unlike many other technologies.

“The use of reparative technologies in orthopaedics is rapidly expanding and medicine is forced to keep up with patient demands and the forces that are placed on their bodies. This is true for all types of patients from young athletes to professional athletes, from weekend warriors to the elderly,” said world renowned sports medicine surgeon Dr. Champ Baker, Jr., of the respected Hughston Clinic in Columbus, GA. “As a result, we are understanding more about reparative medicine options and the science behind them.

“Orthopaedic conditions are the number one cause of disability in patients in the United States and they take a toll on their physical and emotional health, and the ability to support their families. Patients are living longer and are more highly active. They are really trying to maintain their quality of life and function freely,” said Dr. Baker.

The Power of Fat

“Many patients are looking for another option to major invasive surgery. Fat has many important cells and is easy to get from the patient’s body. I believe cells from their own body are the best cells that a patient can use,” said Dr. Baker. “Lipogems may be a great option for patients who have tried physical therapy, nonsteroidal anti-inflammatory drugs, or steroid injections, and other treatments that have not provided enough relief.

“If surgery is needed, Lipogems may be ideal to help provide cushion and support to facilitate the healing environment and optimize recovery,” he added.

Orthopaedic physicians are always looking for convenient technologies that are compliant with current standards. The Lipogems system arrives in a comprehensive kit and uses a minimally invasive procedure to harvest, concentrate, then transfer the patient’s own adipose tissue, typically from the patient’s belly or “love handles.”

The procedure can be performed in the office or surgical setting in under an hour.  The Lipogems system uses only saline to rinse and remove contaminants, typically oil, blood and cell debris, from the harvested fat. Lipogems then resizes, or “microfragments”, the tissue to an optimum size while retaining the fat tissue’s natural and beneficial properties.

The “clean” Lipogems tissue provides cushion and support for the area. In accordance with homologous use, the tissue processed in the Lipogems system may be used to facilitate the natural healing process by supporting the repair, replacement or reconstruction of damaged or injured tissue.

If a patient suffers from multiple orthopaedic conditions, additional fat can be removed (in the same procedure) and processed through the Lipogems technology to help address those additional conditions.

“For procedures performed in the office, there is minimal recovery time and the patients can leave the facility right away and go home with minimal pain medication,” Dr. Baker said. “For patients needing arthroscopic surgery, the introduction of microfragmented fat to their shoulder, hip, or knee may provide cushion and support of the damaged tissue, and optimize the surgical recovery.”

In November 2017, the FDA finalized its rules guiding the use of Human Cellular and Tissue Products.  The Agency reaffirmed that the Lipogems system meets the new guidelines’ criteria for minimal manipulation of the tissue, and that it is intended for homologous use. “Fat has been used for many years in support of the repair or replacement of damaged or injured tissue,” according to Dr. Arnold Caplan of Case Western Reserve University in Cleveland, Ohio. “Fat has a high concentration of reparative cells and is a very powerful tissue. How the fat is processed makes a huge difference on the quality of the tissue and if it meets the new FDA guidelines.”

Dr. Diego Correa, Assistant Professor, Department of Orthopaedics (Division of Sports Medicine) & Diabetes Research Institute- Cell Transplant Center at the University of Miami’s Miller School of Medicine is also impressed by the Lipogems technology.  “Fat has a lot of important structural and reparative cells (including pericytes, adipocytes, and other cells) and they need to be kept together to meet the new guidelines by the FDA. Lipogems is unique because it keeps the cells and tissue intact, and thus functions much like the way it does naturally in the human body—and meets the new FDA guidelines for minimal manipulation.”

Accept No Substitutes

According to Carl Llewellyn, President of Lipogems, USA, “There are many stem cell treatment centers and clinics using technologies that are not FDA cleared or approved.  Many of these clinics are selling stem cell treatments unproven for safety and efficacy, and these lack FDA review and oversight.”

“In fact, many of these clinics are using a process to create a ‘stromal vascular fraction’ of cells isolated from fat tissue, which the FDA considers to be more than minimally manipulated, and thus, requiring significant regulatory oversight as an experimental drug. Lipogems is offered by leading orthopaedic physicians from around the world and encourages patients to seek care from board certified orthopaedic physicians and to ensure the technology they are using is cleared or approved by the FDA.”

Lipogems is pleased to announce its participation at the annual meeting of the American Orthopaedic Society for Sports Medicine (AOSSM), July 5-8, 2018, this year at the Manchester Grand Hyatt in San Diego. (Lipogems will occupy Booth 402 at this year’s gathering.)  The AOSSM meeting draws sports medicine surgeons from around the world and spotlights scientific and clinical presentations about the latest advancements in operative and non-operative care for sports medicine patients.

Arthroscopic Surgery

Arthroscopic surgery is another treatment getting a potential boost from Lipogems. Arthroscopy is the minimally invasive surgical procedure in which an orthopaedic surgeon uses a specialized tool with a tiny camera (i.e. arthroscope) to gain access to the damaged joint. Millions of such procedures are performed each year on the hips, knees, and shoulders of patients young and old. Advancements in technology have improved arthroscopic surgical techniques and patient care. But surgeons continue to be hampered by the limited healing capacity of damaged tissue. But with Lipogems, a patient’s own microfragmented fat may be used to help provide some badly needed cushion and support to facilitate healing.

About Lipogems

Lipogems’ vision is to bring responsible, effective medical technologies to physicians and patients—and to establish the Lipogems system as a mainstream solution.  Lipogems strives to provide physicians and patients with adipose tissue solutions to help maintain or restore patient lifestyles and to improve quality of life and recovery times.

These solutions may offer another option to those who may not want, or who are not candidates for, major, invasive surgery.

The Lipogems system is the company’s first product to receive 510(k) clearance in the United States and is indicated for the harvest, concentration, and transfer of autologous adipose tissue. The system meets new FDA guidelines for minimal manipulation and is intended for homologous use. The company is based in Milan, Italy and Norcross, Georgia, USA. Lipogems is distributed in 27 countries around the world.

For more information, please visit www.lipogems.eu and follow us on Facebook at Lipogems International.

SOURCE Lipogems

Related Links

http://www.understandlipogems.com


shutterstock_1023401719-1.jpg

July 6, 2018 OrthoSpineNews

Oregon State University – 07-06-18

Nanofiber-based wound dressings loaded with vitamin D spur the production of an antimicrobial peptide, a key step forward in the battle against surgical site infections, or SSIs.

The findings by Oregon State University researchers and other collaborators, published Wednesday in Nanomedicine, are important because SSIs are the most common healthcare-associated infection and result in widespread human suffering and economic loss.

Each year in the U.S. alone, nearly 300,000 surgical patients develop an infection within 30 days of their operation – accounting for an estimated $10 billion in additional healthcare costs – and more than 13,000 of those people die.

Researchers used electrospinning to prepare dressings containing the bioactive form of vitamin D: 1,25-dihydroxyvitamin D3, or 1,25(OH)2D3.

“Electrospinning is a versatile, simple, cost-effective and reproducible technique for generating long fibers with nanoscale diameters,” said Adrian Gombart, co-corresponding author and professor of biochemistry and biophysics in OSU’s College of Science. “Electrospun nanofiber wound dressings offer significant advantages over hydrogels or sponges for local drug delivery. They provide several functional and structural advantages, including scar-free healing.”

The dressings the researchers created proved capable of delivering vitamin D on a sustained basis over four weeks, and they significantly induced production of a peptide, hCAP18/LL37, that kills microbes by disrupting their membranes.

 

READ THE REST HERE


12-1.jpg

July 6, 2018 OrthoSpineNews

ENGLEWOOD, Colo.July 5, 2018 /PRNewswire/ — Since its inception, Paragon 28® has obsessed over every aspect of foot and ankle surgery. Committed to creating tailored solutions to improve surgical outcomes, Paragon 28® has launched innovative products and instrumentation to help streamline medical procedures, allow surgeons flexibility in technique and approach, and facilitate reproducible results benefitting both the surgeon and patient.

In a 1st tarsometatarsal (TMT) joint arthrodesis, there is a risk of over shortening the first ray due to over-resection of bone or an inherently short first ray. Attempting to create cuts to achieve the precise amount of IM correction while simultaneously creating congruent surfaces to promote bony apposition at the fusion site can be technically challenging. Avoiding plantar gapping by removing the plantar cartilage from the soft tissue attachments can also prove difficult. Dorsiflexion of the first ray can occur during joint preparation as well, which can lead to transfer metatarsalgia.

The Paragon 28® Lapidus Cut Guide System addresses these concerns by giving the surgeon eight different options for the desired amount of IM correction, while reproducibly guiding cuts through the entirety of the joint resulting in congruent and accurate cartilage removal that minimizes the chance of over-resection. A built in dorsal to plantar taper on cuts made on the metatarsal in two different guide variations is offered to reduce the likelihood of first ray dorsiflexion intraoperatively.

Product Page: http://www.paragon28.com/products/lapidus-cut-guide-system/

Media Contact:  Jim Edson, Vice President of Marketing and Product Management, jedson@paragon28.com

SOURCE Paragon 28


AMPLITUDE-1-123-1.jpg

July 6, 2018 OrthoSpineNews

July 05, 2018

VALENCE, France–(BUSINESS WIRE)–Regulatory News:

AMPLITUDE SURGICAL (Paris:AMPLI) announces that, following the long-term partnership between NATIXIS and ODDO BHF, the liquidity contract relating to its shares initially allocated to Natixis was transferred to ODDO BHF on July 2, 2018.

At the end of the liquidity contract allocated to Natixis relating to the shares of AMPLITUDE SURGICAL (FR0012789667) the following means appeared in the liquidity account:

– Number of shares: 75,320

– Cash balance of the liquidity account: €89,951.89

In the report at 29 December 2017, the liquidity account stood as follows:

– Number of shares: 62,331

– Cash balance of the liquidity account: €133,983.29

By agreement from June 19, 2018 and for a period of one year, renewable by tacit renewal, AMPLITUDE SURGICAL allocated ODDO BHF and NATIXIS with the implementation of a liquidity and market supervision contract for ordinary shares, in accordance with the AMAFI Code of Ethics of March 8, 2011 approved by the AMF on March 21, 2011.

For the implementation of the liquidity contract, the following resources were allocated to ODDO BHF and assigned to the liquidity account:

– Number of shares: 75,320

– Cash balance of the liquidity account: €89,951.89

Next financial press release: 2017-18 Full-Year Sales, Thursday July 26, 2018

About Amplitude Surgical

Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player on the global surgical technology market for lower-limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery covering the main disorders affecting the hip, knee and extremities, and notably foot and ankle surgery. Amplitude Surgical develops, in close collaboration with surgeons, numerous high value-added innovations in order to best meet the needs of patients, surgeons and healthcare facilities. A leading player in France, Amplitude Surgical is developing abroad through its subsidiaries and a network of exclusive distributors and agents. Amplitude Surgical operates on the lower-limb market through the intermediary of its Novastep subsidiaries in France and the United States. Amplitude Surgical distributes its products in more than 30 countries. At June 30, 2016, Amplitude Surgical had a workforce of almost 300 employees and recorded sales of over 80 million euros.

Contacts

Amplitude Surgical
Philippe Garcia, +33 (0)4 75 41 87 41
CFO
philippe.garcia@amplitude-ortho.com
or
NewCap
Investor Relations
Marc Willaume, +33 (0)1 44 71 00 13
amplitude@newcap.eu
or
NewCap
Media Relations
Nicolas Merigeau, +33 (0)1 44 71 98 55
amplitude@newcap.eu


download-1-3.png

July 5, 2018 OrthoSpineNews

SpineMark is the premier global spine service company for the development of Spine Destination Centers and Spine Research Organizations. Through partnerships with hospitals and physicians nationwide and globally, the company develops and operates comprehensive, evidence-based spine centers of excellence to improve the overall quality of life of patients afflicted with spine disorders and injuries. SpineMark is pleased to announce a partnership with Regenexx to provide an innovative, minimally invasive surgical alternative for many common spine conditions. Regenexx will likewise be referring candidates for surgery to SpineMark centers for excellence.

Regenexx provides non-surgical alternatives to treat orthopedic injuries and arthritis, and a broad range of neck and spine conditions such as degenerative disk disease, bulging disks. Founding the field of Interventional Orthopedics, Regenexx cell-based procedures effectively intervene on 70% of orthopedic injuries and conditions where surgery was previously the only solution. This approach enables self-insured employers to save more than 80% on orthopedic costs, all while providing best-in-class outcomes. The Regenexx process of treating musculoskeletal conditions involves a level of physician skill and patented protocols to customize cell based treatments which can only be achieved through Regenexx standards of practice.

“The time is right for the mutual synergies of Regenexx and SpineMark to unite,” said Marcy Rogers, President of SpineMark. “Both companies are privileged to work with the greatest physician leaders in the industry in providing innovative solutions to patients and medical tourists suffering from musculoskeletal and spinal conditions as well as employers, third-party payors and lawyers. We believe this agreement will help support the paradigm shift of services Regenexx and SpineMark offer in their respective fields of interventional orthopedics and minimally invasive spine surgery in the U.S. and abroad.”

“The Regenexx Interventional Orthopedic strategy offers a unique solution for employers to realize immediate savings day-one, dollar one while providing an alternative that employees have chosen over 99% in lieu of surgery,” said Jason Hellickson, CEO of Regenexx. Regenexx clinics are the only regenerative medicine solution with the capability to serve a nationwide footprint with the same standard of care from coast to coast with 60 clinic locations across the country and an additional 70 locations projected by the end of 2019.

About SpineMark 
SpineMark Corporation is a service organization dedicated to transforming the delivery of care for spinal injuries. The company partners with hospitals and physicians across the United States and globally to develop and operate comprehensive, evidence-based spine centers of excellence. By building a global network of spine centers, spine research organizations and state-of-the-art medical conference facilities, SpineMark is improving the overall quality of life of patients afflicted with spine disorders and injuries.

Driven by the specialized experience and expertise of its leadership team and Medical Advisory Board, SpineMark maintains high standards for spine care in its global network, creating clinically validated best practices for spine care that streamline diagnosis and treatment, simplify referrals and accelerate the recovery process.

About Regenexx 
Regenexx is a nationwide network of physicians who practice Interventional Orthopedics, a new specialty that focuses on using the most advanced regenerative-medicine protocols available as an alternative to many orthopedic surgeries. Regenexx has published roughly half of the research world-wide on the use of stem cells for treating orthopedic injuries, and our patented treatment lab-processing and treatment protocols allow us to achieve unmatched results. Regenexx procedures use your body’s natural healing agents including blood platelets and stem cells to repair damaged bone, muscle, cartilage, tendons, and ligaments. We believe in educating patients, offering options, and encouraging people to take an active role in their own treatment.

For more information on Regenexx Corporate visit http://www.regenexxcorporate.com or call 888-547-6667.
For more information on the Regenexx procedures visit http://www.regenexx.com.